Treatment and Schedule

Zanidatamab was diluted in sterile water and delivered intravenous (i.v.) tail-vein injection twice per week in the following concentrations for monotherapy studies: 4, 8, and 16 mg/kg. For combination studies, zanidatamab was delivered at the maximal concentration used (16 mg/kg, i.v., twice per week) in combination with one of the following agents: JQ1 [50 mg/kg, intraperitoneal (i.p.), weekly (qw)], capmatinib [17.5 mg/kg, oral gavage (p.o.), twice per day (b.i.d.)], or crizotinib (100 mg/kg, p.o., qd).